Kristin K. Brown, Laleh Montaser-Kouhsari, Andrew H. Beck, Alex Toker 

Slides:



Advertisements
Similar presentations
Volume 11, Issue 2, Pages (April 2015)
Advertisements

Volume 11, Issue 4, Pages (April 2003)
MAGE-C2 Promotes Growth and Tumorigenicity of Melanoma Cells, Phosphorylation of KAP1, and DNA Damage Repair  Neehar Bhatia, Tony Z. Xiao, Kimberly A.
The impact of the IGF-1 system of cancer cells on radiation response – An in vitro study  Senthiladipan Venkatachalam, Esther Mettler, Christian Fottner,
Volume 33, Issue 2, Pages (January 2009)
ASF1a Promotes Non-homologous End Joining Repair by Facilitating Phosphorylation of MDC1 by ATM at Double-Strand Breaks  Kyung Yong Lee, Jun-Sub Im, Etsuko.
DEPTOR, an mTOR Inhibitor, Is a Physiological Substrate of SCFβTrCP E3 Ubiquitin Ligase and Regulates Survival and Autophagy  Yongchao Zhao, Xiufang Xiong,
Volume 35, Issue 3, Pages (August 2009)
Volume 15, Issue 19, Pages (October 2005)
Volume 54, Issue 1, Pages (April 2014)
RNF168 Promotes Noncanonical K27 Ubiquitination to Signal DNA Damage
Yu-Hsin Chiu, Jennifer Y. Lee, Lewis C. Cantley  Molecular Cell 
Volume 19, Issue 1, Pages (April 2017)
Volume 11, Issue 6, Pages (June 2012)
Volume 12, Issue 8, Pages (August 2015)
Volume 18, Issue 17, Pages (September 2008)
Volume 22, Issue 5, Pages (May 2012)
Volume 23, Issue 1, Pages (July 2006)
Volume 65, Issue 5, Pages e5 (March 2017)
UV-Induced RPA1 Acetylation Promotes Nucleotide Excision Repair
Volume 132, Issue 2, Pages (January 2008)
Wenqi Wang, Nan Li, Xu Li, My Kim Tran, Xin Han, Junjie Chen 
Volume 44, Issue 5, Pages (December 2011)
PIAS1 Promotes Lymphomagenesis through MYC Upregulation
Volume 31, Issue 2, Pages (July 2008)
Volume 68, Issue 2, Pages e6 (October 2017)
MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α
Volume 15, Issue 4, Pages (April 2016)
Volume 29, Issue 3, Pages (February 2008)
Volume 18, Issue 5, Pages (January 2017)
Volume 16, Issue 1, Pages (June 2016)
Volume 35, Issue 3, Pages (August 2009)
Increased Ezrin Expression and Activation by CDK5 Coincident with Acquisition of the Senescent Phenotype  Hai-Su Yang, Philip W Hinds  Molecular Cell 
Volume 2, Issue 6, Pages (June 2002)
MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α
SGK3 Mediates INPP4B-Dependent PI3K Signaling in Breast Cancer
Upregulation of Tenascin-C Expression by IL-13 in Human Dermal Fibroblasts via the Phosphoinositide 3-kinase/Akt and the Protein Kinase C Signaling Pathways 
Volume 66, Issue 4, Pages e5 (May 2017)
Volume 45, Issue 6, Pages (March 2012)
Volume 22, Issue 2, Pages (April 2006)
Volume 27, Issue 6, Pages (September 2007)
Volume 17, Issue 2, Pages (January 2007)
Serine Phosphorylation by mTORC1 Promotes IRS-1 Degradation through SCFβ-TRCP E3 Ubiquitin Ligase  Yosuke Yoneyama, Tomomi Inamitsu, Kazuhiro Chida, Shun-Ichiro.
Volume 16, Issue 24, Pages (December 2006)
The Actin-Bundling Protein Palladin Is an Akt1-Specific Substrate that Regulates Breast Cancer Cell Migration  Y. Rebecca Chin, Alex Toker  Molecular.
Volume 10, Issue 3, Pages (September 2006)
Volume 59, Issue 6, Pages (September 2015)
Volume 20, Issue 4, Pages (November 2005)
Volume 14, Issue 1, Pages (July 2008)
Volume 18, Issue 12, Pages (March 2017)
Volume 20, Issue 3, Pages (July 2017)
Volume 59, Issue 4, Pages (August 2015)
Rsk1 mediates a MEK–MAP kinase cell survival signal
Volume 96, Issue 6, Pages (March 1999)
Volume 47, Issue 4, Pages (August 2012)
Volume 25, Issue 5, Pages (March 2007)
Mst1 Is an Interacting Protein that Mediates PHLPPs' Induced Apoptosis
Volume 30, Issue 6, Pages (June 2009)
MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway
Yap1 Phosphorylation by c-Abl Is a Critical Step in Selective Activation of Proapoptotic Genes in Response to DNA Damage  Dan Levy, Yaarit Adamovich,
Volume 13, Issue 15, Pages (August 2003)
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Volume 34, Issue 6, Pages (June 2009)
Volume 26, Issue 12, Pages e4 (March 2019)
Phosphorylation and Functional Inactivation of TSC2 by Erk
Volume 129, Issue 5, Pages (June 2007)
Volume 65, Issue 5, Pages e4 (March 2017)
Volume 31, Issue 2, Pages (July 2008)
Volume 43, Issue 2, Pages (July 2011)
Volume 9, Issue 2, Pages (October 2014)
Presentation transcript:

MERIT40 Is an Akt Substrate that Promotes Resolution of DNA Damage Induced by Chemotherapy  Kristin K. Brown, Laleh Montaser-Kouhsari, Andrew H. Beck, Alex Toker  Cell Reports  Volume 11, Issue 9, Pages 1358-1366 (June 2015) DOI: 10.1016/j.celrep.2015.05.004 Copyright © 2015 The Authors Terms and Conditions

Cell Reports 2015 11, 1358-1366DOI: (10.1016/j.celrep.2015.05.004) Copyright © 2015 The Authors Terms and Conditions

Figure 1 Influence of Doxorubicin on Akt Activity and Contribution of PI3K/Akt Signaling toward Cell Survival following Doxorubicin Exposure (A and B) MCF10A cells were serum-starved and treated with (A) 2 μM doxorubicin over a 10-hr time course or (B) increasing concentrations of doxorubicin for 10 hr. (C) T47D and SUM159 cells were serum-starved and treated with 0.5 μM doxorubicin for 24 hr. (D) MCF10A cells were serum-starved and pre-treated with 2 μM BKM120, 2 μM MK2206, or 2 μM Nu7441 for 30 min before exposure to 2 μM doxorubicin for 10 hr. (E) MCF10A cells were pre-treated with 1 μM MK2206, 1 μM BKM120, or 1 μM Nu7441 for 24 hr before exposure to increasing concentrations of doxorubicin for an additional 48 hr. Cell viability is expressed as a percentage of viability observed in untreated cells (t test; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). (F) MCF10A cells were pre-treated with 1 μM MK2206, 1 μM BKM120, or 1 μM Nu7441 for 24 hr before the addition of 0.5 μM doxorubicin for an additional 24 hr. (G) T47D, SUM159, and MCF7 cells were pre-treated with 1 μM MK2206 or 1 μM BKM120 for 24 hr before exposure to 0.5 μM doxorubicin for an additional 48 hr. Cell viability is expressed as a percentage of viability observed in untreated cells (t test; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). Cell Reports 2015 11, 1358-1366DOI: (10.1016/j.celrep.2015.05.004) Copyright © 2015 The Authors Terms and Conditions

Figure 2 MERIT40 Is an Akt Substrate (A) Domain structure of MERIT40 highlights the Akt consensus phosphorylation motif (24RPRTRS29), two TNKS-binding motifs (28RSNPEGAE35 and 48RSEGEGE54), and a von Willebrand A domain (VWA). (B) HA-Flag-MERIT40 and MERIT40 Ser29Ala were used as substrates in an in vitro kinase assay with recombinant active Akt1, Akt2, or Akt3. (C) MCF10A cells were serum-starved and pre-treated with the indicated inhibitors for 30 min before stimulation with IGF-1 for 30 min. (D) MCF10A cells were infected with empty vector or Akt small hairpin RNA (shRNA) constructs. Cells were serum-starved before stimulation with IGF-1 for 30 min. (E) MCF10A cells were infected with vector control, PIK3CA wild-type (WT), PIK3CA E545K (EK), or PIK3CA H1047R (HR) constructs and serum-starved. (F) MCF10A cells were transfected with vector control or myristoylated Akt alleles (myrAkt1/2/3) and serum-starved. (G) MCF10A cells were serum-starved and exposed to 2 μM doxorubicin over a 10-hr time course. See also Figure S1. (H) MCF10A cells were serum-starved and pre-treated with the indicated inhibitors for 30 min before exposure to 2 μM doxorubicin for 10 hr. (I) MCF10A cells were infected with empty vector or Akt shRNA constructs. Cells were serum-starved before exposure to 2 μM doxorubicin for 10 hr. Cell Reports 2015 11, 1358-1366DOI: (10.1016/j.celrep.2015.05.004) Copyright © 2015 The Authors Terms and Conditions

Figure 3 Effect of MERIT40 Phosphorylation on Stability and Formation of the BRCA1-A Complex (A) MCF10A cells were infected with empty vector or MERIT40 shRNA constructs and empty vector, WT MERIT40, or MERIT40 S29A mutant expression constructs. (B) MCF10A cells were serum-starved before exposure to 2 μM doxorubicin for 1 hr. Endogenous BRCA1 was immunoprecipitated from nuclear extracts and co-immunoprecipitation with endogenous TNKS and Rap80 was monitored. (C) HEK293T cells were transfected with WT or mutant MERIT40 constructs and a WT TNKS expression plasmid. HA-tagged MERIT40 was immunoprecipitated from cells and co-immunoprecipitation of myc-tagged TNKS was monitored. Alternatively, myc-tagged TNKS was immunoprecipitated from cells and co-immunoprecipitation of HA-tagged TNKS was monitored. (D) MCF10A cells were infected with WT or mutant MERIT40 constructs. Cells were serum-starved and exposed to 2 μM doxorubicin for 1 hr. HA-tagged MERIT40 was immunoprecipitated from cells and co-immunoprecipitation with endogenous TNKS and Rap80 was monitored. (E) MCF10A cells were serum-starved and pre-treated with 2 μM MK2206 for 30 min before exposure to 2 μM doxorubicin for 1 hr. Endogenous MERIT40 was immunoprecipitated from cells and co-immunoprecipitation with endogenous TNKS and Rap80 was monitored. (F) MCF10A cells were serum-starved and treated with 2 μM doxorubicin for 1 hr or IGF-1 for 30 min. Endogenous MERIT40 was immunoprecipitated from cells and co-immunoprecipitation with endogenous TNKS and Rap80 was monitored. (G) T47D cells were infected with empty vector or a MERIT40 shRNA construct and empty vector, WT MERIT40, or MERIT40 S29A mutant expression constructs. Cells were exposed to 0.5 μM doxorubicin for 1 hr, washed with PBS, and incubated in fresh media for an additional hour. Rap80 focus formation was monitored by immunofluorescence. Cell Reports 2015 11, 1358-1366DOI: (10.1016/j.celrep.2015.05.004) Copyright © 2015 The Authors Terms and Conditions

Figure 4 Contribution of MERIT40 Phosphorylation toward the Resolution of DNA Damage and Cell Survival following Doxorubicin Exposure and Detection of Phospho-MERIT40 in Human Breast Tumors (A) T47D cells were infected with empty vector or a MERIT40 shRNA construct and empty vector, WT MERIT40, or MERIT40 S29A mutant expression constructs. Cells were exposed to 0.5 μM doxorubicin for 1 hr, washed with PBS, and incubated in fresh media for an additional 6 hr. See also Figure S2. (B) T47D cells were infected with empty vector or a MERIT40 shRNA construct and empty vector, WT MERIT40, or MERIT40 S29A mutant expression constructs. Cells were exposed to 0.5 μM doxorubicin for 1 hr, washed with PBS, and incubated in fresh media for an additional 6 hr. Phosphorylation of histone H2A.X was monitored by immunofluorescence. (C) The percentage of cells with nuclear p-Histone H2A.X foci was quantified by counting 200 cells in each treatment condition (t test, ∗∗p < 0.01). (D) MCF10A cells were transfected with control or MERIT40 small interfering RNA (siRNA) constructs and empty vector, WT MERIT40, or MERIT40 S29A mutant expression constructs. Cells were exposed to 0.2 μM doxorubicin for 48 hr. Cell viability is expressed as a percentage of viability observed in untreated cells (t test, ∗p < 0.05). (E) MCF10A cells were transfected with control or MERIT40 siRNA constructs and empty vector, WT MERIT40, or MERIT40 S29A mutant expression constructs. Cells were exposed to 0.2 μM doxorubicin for 24 hr. (F) Detection of p-MERIT40 and MERIT40 in invasive breast tumor tissue samples by IHC is shown. (G) Relationship between p-MERIT40 IHC staining in human breast tumor samples and ER status is shown. Cell Reports 2015 11, 1358-1366DOI: (10.1016/j.celrep.2015.05.004) Copyright © 2015 The Authors Terms and Conditions